---
title: "Imbruvica (ibrutinib), all indications: Specific populations questions"
description: "Specific populations questions on Imbruvica (ibrutinib) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pregnancy and breastfeeding. Questions: Does kidney impairment affect Imbruvica levels? Can Imbruvica be used during pregnancy? Can Imbruvica be used while breastfeeding? Is Imbruvica safe and effective in adults 65 and older? 1 further question follow. 5 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/imbruvica/specific-populations"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Imbruvica (ibrutinib), all indications: Specific populations questions

Manufacturer: Pharmacyclics LLC; Janssen Biotech, Inc.  
Prescribing information: [Imbruvica](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf)  
Indication pages: [Chronic lymphocytic leukemia and small lymphocytic lymphoma](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma)

## Specific populations

<a id="imbruvica-kidney-impairment"></a>

### Does kidney impairment affect Imbruvica levels?

> “Mild and moderate renal impairment (creatinine clearance [CLcr] > 25 mL/min as estimated by 
> Cockcroft-Gault equation) had no influence on the exposure of ibrutinib. No data is available in 
> patients with severe renal impairment (CLcr < 25 mL/min) or in patients on dialysis.”

Source: [IMBRUVICA: Prescribing information, page 36, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=36)

<a id="imbruvica-older-adults"></a>

### Is Imbruvica safe and effective in adults 65 and older?

> “Of 992 patients in clinical studies of IMBRUVICA for B-cell malignancies or cGVHD, 62% 
> were ≥ 65 years of age, while 22% were ≥ 75 years of age [see Clinical Studies (14.1, 14.2, 
> 14.3)]. No overall differences in effectiveness were observed between younger and older 
> patients. Anemia (all grades), pneumonia (Grade 3 or higher), thrombocytopenia, hypertension, 
> and atrial fibrillation occurred more frequently among older patients treated with IMBRUVICA 
> [see Adverse Reactions (6.1)].”

Source: [IMBRUVICA: Prescribing information, page 32, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=32)

<a id="imbruvica-overdose"></a>

### What should be done after an Imbruvica overdose?

> “There is no specific experience in the management of ibrutinib overdose in patients. One healthy 
> subject experienced reversible Grade 4 hepatic enzyme increases (AST and ALT) after a dose of 
> 1680 mg. Closely monitor patients who ingest more than the recommended dosage and provide 
> appropriate supportive treatment.”

Source: [IMBRUVICA: Prescribing information, page 33, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=33)

## Pregnancy and breastfeeding

<a id="imbruvica-pregnancy"></a>

### Can Imbruvica be used during pregnancy?

> “IMBRUVICA can cause fetal harm based on findings from animal studies. There are no 
> available data on IMBRUVICA use in pregnant women to inform a drug-associated risk of major 
> birth defects and miscarriage. In animal reproduction studies, administration of ibrutinib to 
> pregnant rats and rabbits during the period of organogenesis at exposures up to 3-20 times the 
> clinical dose of 420 mg daily produced embryofetal toxicity including structural abnormalities 
> (see Data). Advise pregnant women of the potential risk to a fetus. 
> All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. 
> The estimated background risk of major birth defects and miscarriage for the indicated 
> population is unknown. In the U.S. general population, the estimated background risk of major 
> birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, 
> respectively.”

Source: [IMBRUVICA: Prescribing information, page 30, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=30)

> “Pregnancy Testing 
> Verify pregnancy status in females of reproductive potential prior to initiating IMBRUVICA. 
> Contraception 
> Females 
> Advise females of reproductive potential to use effective contraception during treatment with 
> IMBRUVICA and for 1 month after the last dose.   
> Males 
> Advise males with female partners of reproductive potential to use effective contraception during 
> treatment with IMBRUVICA and for 1 month following the last dose.”

Source: [IMBRUVICA: Prescribing information, page 31, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=31)

<a id="imbruvica-breastfeeding"></a>

### Can Imbruvica be used while breastfeeding?

> “There is no information regarding the presence of ibrutinib or its metabolites in human milk, the 
> effects on the breastfed child, or the effects on milk production. Because of the potential for 
> serious adverse reactions in the breastfed child, advise women not to breastfeed during treatment 
> with IMBRUVICA and for 1 week after the last dose.”

Source: [IMBRUVICA: Prescribing information, page 31, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=31)

## Related pages
- [Medical information: Imbruvica (ibrutinib): All indications](https://www.evicenter.com/medical-information/imbruvica)
- [Indication](https://www.evicenter.com/medical-information/imbruvica/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/imbruvica/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/imbruvica/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/imbruvica/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/imbruvica/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/imbruvica/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/imbruvica/access-and-coverage)
